Eldelumab (MDX-1100 or BMS-936557) is a fully humanized antibody (type IgG1 kappa developed by Bristol-Myers Squibb and Medarex) targeting CXCL10 [37] that is being studied as a therapy for multiple autoimmune and autoinflammatory diseases including rheumatoid arthritis (NCT01017367), ulcerative colitis (NCT00656890, NCT01294410), and Crohn’s disease (NCT01466374). This evidence concerns the gene CXCL10 and ulcerative colitis.